secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001664710-24-000055
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros reports durable transfusion independence in Phase 2 MDS trial; plans registrational Phase 3
--------------------------------------------------------------------------------

- Overall erythroid response 55.6% (45/81) in modified ITT patients; 41.3% (26/63) of TI-evaluable achieved ≥8-week transfusion independence.
- Median duration of TI not reached; 42.3% (11/26) of TI responders had responses >1 year, all ongoing as of April 3, 2024.
- In MF Phase 2, 60.6% (20/33) of transfusion-dependent patients had reduced transfusion burden; 52.9% (9/17) with large spleens had volume reductions at Week 24.
- Preclinical MF model data shows elritercept promotes erythropoiesis, mitigates anemia, and improves muscle mass/function.
- Company plans to initiate a registrational Phase 3 trial in lower-risk MDS following positive FDA feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000055/0001664710-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000055/kros-20240617.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer